Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Milano Bicocca
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with clinically definite diagnosis of relapsing remitting MS (RRMS);
Male or female subjects, 18 to 65 years old;
Expanded Disability Status Scale (EDSS) score ranging from 0 to 5.5 (included);
Predominant deficits in either attention/information processing;
Fluent Italian speakers;
Normal or corrected-to-normal vision;
Ability to understand the purpose and risk of the study and provide signed informed consent.
You may not be if
MS patients in different phase of the disease (as primary/secondary progressive MS; benign MS) or Clinical Isolated Syndrome (CIS) patients;
Exclusive cognitive impairment in different domains (e.g., memory);
CT/neuromodulation program ongoing or in the preceding 6 months;
Clinical exacerbations, neuroradiological activity of the disease, modification of EDSS score and disease modifying treatments/steroids during the last 3 months preceding study enrolment;
Significant medical disorders or other major systemic, psychiatric, neurological disorders or alcohol/substance abuse that could interfere with cognitive functioning;
Antidepressant/psychoactive drugs in the past 3 months;
Contraindications to tDCS (intracranial metallic plates, implanted devices, skin disease, superficial injury and fracture or infraction of skull in the stimulation area, epilepsy, pregnancy, etc).
Clareo Health | tDCS to Enhance Cognitive Training in Multiple Sclerosis
